A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.

NCT04469127 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer Stage IV

Interventions

DRUG: Lutetium-177-DOTAGA-IAC

Sponsor

Advanced Imaging Projects, LLC

Collaborators

[object Object]
[object Object]